Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional Results available

Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin

ClinicalTrials.gov ID: NCT02429258

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02429258. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Effect of Dapagliflozin on 24-hour Blood Glucose in Type 2 Diabetes Patients Inadequately Controlled With Either Metformin Or Insulin

Study identification

NCT ID
NCT02429258
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
AstraZeneca
Industry
Enrollment
226 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 2015 (Type not available)
Primary completion
Oct 2015 (Actual)
Completion
Oct 2015 (Actual)
Last update posted
Jun 14, 2017

2015

United States locations

U.S. sites
26
U.S. states
16
U.S. cities
26
Facility City State ZIP Site status
Research Site Birmingham Alabama — —
Research Site Phoenix Arizona — —
Research Site Huntington Park California — —
Research Site Los Angeles California — —
Research Site Sacramento California — —
Research Site San Diego California — —
Research Site West Hills California — —
Research Site Cooper City Florida — —
Research Site Miami Florida — —
Research Site Evanston Illinois — —
Research Site Oxon Hill Maryland — —
Research Site Henderson Nebraska — —
Research Site Brooklyn New York — —
Research Site Rochester New York — —
Research Site Greensboro North Carolina — —
Research Site Cincinnati Ohio — —
Research Site Dublin Ohio — —
Research Site Franklin Ohio — —
Research Site Eugene Oregon — —
Research Site Lansdale Pennsylvania — —
Research Site Spartanburg South Carolina — —
Research Site Bartlett Tennessee — —
Research Site Dallas Texas — —
Research Site Houston Texas — —
Research Site Hurst Texas — —
Research Site Renton Washington — —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02429258, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 14, 2017 · Synced Nov 14, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.